Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Drugmaker Lupin has launched Drospirenone, Ethinyl Estradiol, Levomefolate Calcium tablets and Levomefolate Calcium tablets for preventing pregnancy in the US.
Image: Lupin has launched contraceptive drug in the US. Photo: courtesy of Areeya / FreeDigitalPhotos.net.
Subscribe to our email newsletter
The company has secured approval from the Food and Drug Administration for drugs with strengths of 3 mg/0.02 mg/0.451 mg and 0.451 mg (EQ Beyaz).
Lupin’s Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg, are the generic equivalent of Bayer’s Beyaz® Tablets. It is indicated for use by women to:prevent pregnancy;
treat symptoms of premenstrual dysphoric disorder (PMDD) for women who choose to use an oral contraceptive for contraception;
treat moderate acne for women at least 14 years old, only if the patient desires an oral contraceptive for birth control; and
raise folate levels in women who choose to use an oral contraceptive for contraception.
Drospirenone, Ethinyl Estradiol and Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg had annual sales of approximately USD 80.8 million in the US (IQVIA MAT June 2018).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Lupin is the 8th largest generics pharmaceutical company both in terms of market capitalization (30th June 2018, Bloomberg) and revenues (31st March 2018, Bloomberg LTM) globally.
The Company is the 4th largest pharmaceutical player in the US by prescriptions (IQVIA MAT June 2018); 3rd largest Indian pharmaceutical company by global revenues (31st March 2018, Bloomberg LTM); 6th largest generic pharmaceutical player in Japan and 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT June 2018).
Source: Company Press Release
